Table 3 Odds ratios and 95% CI for hypertension of subjects according to baseline serum uric acid in the cross-sectional study

Model 1

Men/Women (mg/dL)

Total

N

odds ratio (95% CI)

p-value

N

odds ratio (95% CI)

p-value

SUA-1

0.6–5.1/0.7–4.0

449

52/133

1.0

–

113/151

1.0

–

SUA-2

5.2–5.9/4.1–4.7

417

72/109

0.59 (0.38–0.92)

0.019

95/141

1.11 (0.78–1.59)

0.564

SUA-3

6.0–6.7/4.8–5.4

382

64/98

0.60 (0.38–0.94)

0.025

66/154

1.75 (1.20–2.55)

0.004

SUA-4

6.8–9.9/5.5–9.3

402

49/127

1.01 (0.64–1.61)

0.955

64/162

1.89 (1.30–2.77)

0.001

Continuous variable

1650

237/467

1.00 (0.87–1.15)

0.957

338/608

1.27 (1.12–1.43)

< 0.001

Model 2

Men/Women (mg/dL)

Total

N

odds ratio (95% CI)

p-value

N

odds ratio (95% CI)

p-value

SUA-1

0.6–5.1/0.7–4.0

449

52/133

1.0

–

113/151

1.0

–

SUA-2

5.2–5.9/4.1–4.7

417

72/109

0.67 (0.43–1.05)

0.079

95/141

1.05 (0.73–1.53)

0.786

SUA-3

6.0–6.7/4.8–5.4

382

64/98

0.70 (0.44–1.10)

0.124

66/154

1.84 (1.24–2.73)

0.003

SUA-4

6.8–9.9/5.5–9.3

402

49/127

1.22 (0.76–1.95)

0.420

64/162

1.83 (1.23–2.73)

0.003

Continuous variable

1650

237/467

1.07 (0.92–1.23)

0.390

338/608

1.27 (1.12–1.44)

< 0.001

Model 3

Men/Women (mg/dL)

Total

N

odds ratio (95% CI)

p-value

N

odds ratio (95% CI)

p-value

SUA-1

0.6–5.1/0.7–4.0

449

52/133

1.0

–

113/151

1.0

–

SUA-2

5.2–5.9/4.1–4.7

417

72/109

0.62 (0.38–1.00)

0.051

95/141

0.87 (0.58–1.30)

0.495

SUA-3

6.0–6.7/4.8–5.4

382

64/98

0.62 (0.37–1.03)

0.065

66/154

1.34 (0.87–2.07)

0.191

SUA-4

6.8–9.9/5.5–9.3

402

49/127

0.86 (0.50–1.49)

0.598

64/162

1.06 (0.66–1.69)

0.818

Continuous variable

1650

237/467

0.96 (0.81–1.13)

0.619

338/608

1.06 (0.91–1.23)

0.438